Login to Your Account



Fate of Myeloma Study Uncertain

Keryx, Aeterna Priorities Shift After Perifosine Misses in CRC

By Jennifer Boggs
Managing Editor

Tuesday, April 3, 2012
Despite high hopes for oral Akt inhibitor perifosine, the drug failed to improve overall survival in a Phase III colorectal cancer (CRC) trial, sending shares of partners Keryx Pharmaceuticals Inc. and Aeterna Zentaris Inc. tumbling Monday and shifting investor attention to each firm's other late-stage programs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription